CSCIF (CSCIF) Stock Price & Analysis
CSCIF (CSCIF) rose 0.49% to USD 2.05 as of June 10, 2026 at 05:53 UTC, according to Nexqual real-time market data.
CSCIF last closed at USD 2.04; the session ranged USD 2.05–2.05 on volume of 1,099 shares. Market capitalization is $6.53M, with a 52-week range of USD 0.79–4.4 (OQB). Source: Nexqual, June 10, 2026 at 05:53 UTC.
Key Statistics (as of June 10, 2026 at 05:53 UTC)
| Price | USD 2.05 |
|---|---|
| Change | ▲ 0.49% (up) |
| Previous Close | USD 2.04 |
| Open | USD 2.05 |
| Day Range | USD 2.05 – 2.05 |
| 52-Week Range | USD 0.79 – 4.4 |
| Volume | 1,099 shares |
| Market Cap | $6.53M |
| Exchange | OQB |
Technical Analysis (CSCIF)
Nexqual's technical model rates CSCIF "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 05:53 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 53.74 (neutral) |
| vs SMA50 | Above (USD 1.91) |
| MACD | 0.03 (positive) |
Analyst Ratings (CSCIF)
Wall Street analysts rate CSCIF "None", per Nexqual as of June 10, 2026 at 05:53 UTC.
| Consensus Rating | None |
|---|
Earnings (CSCIF)
| Next Earnings Date | 2026-05-12 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-12-31 | USD -4.64 vs est -3.88 ▼ miss |
| 2023-09-30 | USD -3.4 vs est -2.44 ▼ miss |
| 2023-06-30 | USD -2.08 vs est -3.48 ▲ beat |
| 2023-03-31 | USD -3.52 vs est -4.28 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:53 UTC.
Financials & Fundamentals (CSCIF)
| Total Revenue | $8.00M |
|---|---|
| Revenue Growth (YoY) | +36.10% |
| Gross Margin | +37.44% |
| Operating Margin | -38.66% |
| Profit Margin | +50.68% |
| ROE | -61.79% |
| Debt / Equity | 13.21 |
| Current Ratio | 5.57 |
| Total Cash | $5.00M |
| Total Debt | $2.02M |
| Free Cash Flow | $-7.42M |
Source: Nexqual, June 10, 2026 at 05:53 UTC.
Financial Health Score (CSCIF)
Nexqual rates CSCIF's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:53 UTC.
| Growth | Critical — Revenue -20% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $5M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$7M, burning cash |
| Efficiency | Critical — ROE -62%, ROA -21.3% |
Ownership (CSCIF)
| Insider Ownership | +0.55% |
|---|---|
| Institutional Ownership | +8.08% |
| Shares Outstanding | 3.18M |
| Float | 3.17M |
| Short % of Float | +0.26% |
Source: Nexqual, June 10, 2026 at 05:53 UTC.
Leadership (CSCIF)
CSCIF is led by Peter Harry Puccetti, Interim CEO & Chairman, per Nexqual as of June 10, 2026 at 05:53 UTC.
| Interim CEO & Chairman | Peter Harry Puccetti |
|---|---|
| Senior VP of Finance & CFO | Giuliano La Fratta |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BGMSP | Bio Green Med Solution Inc. | USD 0.7 | ▲ 0.86% |
| ATOS | Atossa Therapeutics, Inc. | USD 4.41 | ▼ 1.34% |
| TLPH | Talphera, Inc. | USD 0.82 | ▲ 4.56% |
| OGEN | Oragenics Inc. | USD 0.6 | ▲ 1.69% |
| AGEN | Agenus Inc. | USD 3.11 | ▼ 3.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:53 UTC. This page is informational and not investment advice.